Overview
Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
Status:
Completed
Completed
Trial end date:
2012-06-01
2012-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is designed to assess the potential difference in Fasting Plasma Glucose (FPG) lowering efficacy between the two DPP-4 inhibitors vildagliptin and sitagliptin, both after a two weeks treatment on top of metformin.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Sitagliptin Phosphate
Vildagliptin
Criteria
Inclusion Criteria:Patients with type 2 diabetes 18 to 85 years Metformin monotherapy > 4 weeks HbA1c 6.5 -
9.5%
Exclusion Criteria:
FPG > 270 mg/dl Use of other antidiabetic drugs than metformin major cardiovascular event
in the last 6 months (MI, stroke…)